MI
Monashee Investment Management LLC
13F filer · CIK 0001627608Reported Aug 13, 2026
Net seller this quarter
13F portfolio value$59.6MU.S. long equity reported on 13F
Positions2018 new · 37 closed
Net flow last quarter-$131MBuys minus sells
Top 10 positions weight64.2%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 13, 202620 positions | |||||
| $5.09M | 8.54% | Not reported | New | Q2 2026 | |
| $5.03M | 8.44% | Not reported | New | Q2 2026 | |
| $5M | 8.38% | 0.48% | -64.8% | Q1 2024 | |
| $4.49M | 7.53% | 0.01% | New | Q2 2026 | |
| $4.44M | 7.45% | 0.06% | New | Q2 2026 | |
| $3.9M | 6.55% | 0.08% | -14.3% | Q1 2024 | |
| $3.13M | 5.25% | 0.06% | New | Q2 2026 | |
| $2.6M | 4.36% | Not reported | New | Q2 2026 | |
| $2.47M | 4.14% | 0.02% | Not reported | Q2 2020 | |
| $2.14M | 3.60% | 0.00% | New | Q2 2026 | |
| $2.12M | 3.56% | Not reported | New | Q2 2026 | |
| $2.07M | 3.48% | 0.06% | Not reported | Q3 2019 | |
| $1.88M | 3.16% | 0.01% | New | Q2 2026 | |
| $1.79M | 3.00% | 0.06% | New | Q2 2026 | |
| $1.61M | 2.71% | Not reported | Not reported | Q3 2025 | |
| $1.46M | 2.45% | 0.10% | Not reported | Q2 2022 | |
| $1.43M | 2.39% | Not reported | New | Q2 2026 | |
| $1.36M | 2.29% | 0.06% | Not reported | Q3 2020 | |
| $1.13M | 1.90% | 1.71% | Not reported | Q4 2025 | |
| $1.02M | 1.71% | 0.05% | New | Q2 2026 | |
| Q1 2026Reported May 13, 202639 positions | |||||
| TPTERNTerns Pharmaceuticals, Inc. | $15.8M | 8.60% | 0.26% | +52.0% | Q4 2022 |
| $13.4M | 7.26% | Not reported | Not reported | Q4 2025 | |
| $12.4M | 6.76% | 0.04% | New | Q1 2026 | |
| $10.2M | 5.57% | Not reported | New | Q1 2026 | |
| $10.2M | 5.56% | 1.44% | +5.2% | Q1 2024 | |
| $7.2M | 3.91% | 0.49% | +6.2% | Q4 2025 | |
| $6.59M | 3.59% | 0.08% | +33.3% | Q2 2022 | |
| $5.24M | 2.85% | Not reported | New | Q1 2026 | |
| $4.99M | 2.71% | 0.03% | -32.9% | Q2 2019 | |
| $4.6M | 2.50% | 0.09% | +75.0% | Q1 2024 | |
| $4.12M | 2.24% | 0.50% | -2.1% | Q4 2025 | |
| $3.73M | 2.03% | Not reported | New | Q1 2026 | |
| $3.18M | 1.73% | 0.00% | New | Q1 2026 | |
| $3.16M | 1.72% | 0.13% | New | Q1 2026 | |
| $2.93M | 1.60% | 0.24% | Not reported | Q3 2024 | |
| $2.92M | 1.59% | 0.04% | -64.9% | Q2 2025 | |
| $2.64M | 1.43% | 0.49% | +21.9% | Q3 2025 | |
| $2.61M | 1.42% | Not reported | New | Q1 2026 | |
| $2.6M | 1.41% | Not reported | Not reported | Q3 2025 | |
| $2.46M | 1.34% | 0.28% | New | Q1 2026 | |
| $2.41M | 1.31% | 0.02% | -77.8% | Q1 2023 | |
| $2.38M | 1.29% | 0.05% | Not reported | Q4 2016 | |
| $2.33M | 1.27% | 0.04% | New | Q1 2026 | |
| $2.22M | 1.21% | 0.01% | Not reported | Q2 2024 | |
| $2.18M | 1.19% | 0.48% | +8.5% | Q4 2025 | |
| $2.06M | 1.12% | Not reported | New | Q1 2026 | |
| $1.92M | 1.04% | 0.66% | New | Q1 2026 | |
| $1.88M | 1.02% | 0.36% | Not reported | Q4 2016 | |
| $1.47M | 0.80% | 0.19% | New | Q1 2026 | |
| $1.45M | 0.79% | 0.11% | New | Q1 2026 | |
| $1.39M | 0.76% | Not reported | New | Q1 2026 | |
| $1.37M | 0.74% | 0.14% | -74.1% | Q4 2021 | |
| $1.23M | 0.67% | Not reported | New | Q1 2026 | |
| $1.19M | 0.65% | 0.00% | New | Q1 2026 | |
| $1.18M | 0.64% | Not reported | New | Q1 2026 | |
| $953K | 0.52% | 0.21% | -42.9% | Q3 2025 | |
| $896K | 0.49% | 0.06% | New | Q1 2026 | |
| $582K | 0.32% | 0.10% | New | Q1 2026 | |
| $67.6K | 0.04% | 0.93% | New | Q1 2026 | |
| Q4 2025Reported Feb 12, 202638 positions | |||||
| $15.6M | 8.82% | 0.11% | +12.5% | Q1 2023 | |
| $12.6M | 7.10% | Not reported | New | Q4 2025 | |
| $10.5M | 5.90% | 0.03% | Not reported | Q2 2021 | |
| $10.3M | 5.78% | 0.06% | Not reported | Q2 2024 | |
| $8.7M | 4.90% | 0.02% | Not reported | Q1 2015 | |
| TPTERNTerns Pharmaceuticals, Inc. | $7.97M | 4.49% | 0.18% | Not reported | Q4 2022 |
| $7.78M | 4.38% | 0.12% | Not reported | Q2 2025 | |
| $7.77M | 4.38% | 0.20% | +16.7% | Q3 2025 | |
| $7.65M | 4.31% | 0.05% | -50.0% | Q2 2019 | |
| $7.61M | 4.29% | 1.71% | Not reported | Q1 2024 | |
| $5.94M | 3.35% | Not reported | -8.0% | Q3 2025 | |
| $5.9M | 3.33% | 0.24% | Not reported | Q1 2024 | |
| $5.56M | 3.14% | 0.04% | New | Q4 2025 | |
| $5.37M | 3.03% | 0.56% | -20.0% | Q4 2021 | |
| $4.77M | 2.69% | 0.06% | -25.0% | Q2 2022 | |
| $4.08M | 2.30% | 0.69% | New | Q4 2025 | |
| $3.98M | 2.24% | 0.46% | New | Q4 2025 | |
| $3.82M | 2.15% | Not reported | New | Q4 2025 | |
| $3.23M | 1.82% | 0.05% | -11.1% | Q1 2024 | |
| $3.14M | 1.77% | 0.58% | New | Q4 2025 | |
| $3.1M | 1.75% | 0.43% | Not reported | Q1 2019 | |
| $3.08M | 1.73% | Not reported | New | Q4 2025 | |
| $2.78M | 1.56% | 0.16% | New | Q4 2025 | |
| $2.66M | 1.50% | 0.44% | New | Q4 2025 | |
| $2.43M | 1.37% | 0.46% | -57.5% | Q3 2025 | |
| $2.24M | 1.26% | 0.07% | Not reported | Q3 2020 | |
| $2.21M | 1.25% | 0.37% | -60.6% | Q3 2025 | |
| $2.01M | 1.13% | 0.01% | New | Q4 2025 | |
| $1.83M | 1.03% | 0.32% | New | Q4 2025 | |
| $1.68M | 0.95% | 0.12% | New | Q4 2025 | |
| $1.57M | 0.89% | 0.60% | New | Q4 2025 | |
| $1.51M | 0.85% | 0.06% | New | Q4 2025 | |
| $1.16M | 0.65% | 0.04% | Not reported | Q2 2021 | |
| $1.08M | 0.61% | 0.18% | New | Q4 2025 | |
| $764K | 0.43% | 1.36% | +12.4% | Q4 2020 | |
| $666K | 0.38% | 0.23% | New | Q4 2025 | |
| $632K | 0.36% | 0.82% | New | Q4 2025 | |
| $530K | 0.30% | 0.91% | New | Q4 2025 | |
| Q3 2025Reported Nov 12, 202557 positions | |||||
| $10.4M | 5.18% | 0.10% | -21.6% | Q2 2019 | |
| $10.4M | 5.17% | 0.47% | New | Q3 2025 | |
| $9.65M | 4.81% | 0.93% | New | Q3 2025 | |
| $7.27M | 3.63% | Not reported | New | Q3 2025 | |
| $6.82M | 3.40% | Not reported | New | Q3 2025 | |
| $6.41M | 3.20% | 0.04% | Not reported | Q3 2022 | |
| $6.11M | 3.05% | 0.00% | +68.8% | Q3 2024 | |
| $6.05M | 3.02% | Not reported | New | Q3 2025 | |
| $6.04M | 3.01% | 0.18% | New | Q3 2025 | |
| $5.98M | 2.98% | 1.10% | New | Q3 2025 | |
| $5.69M | 2.84% | 0.09% | Not reported | Q2 2024 | |
| $5.6M | 2.79% | 0.11% | -53.5% | Q1 2023 | |
| $5.5M | 2.74% | 0.08% | Not reported | Q2 2022 | |
| $4.62M | 2.30% | Not reported | New | Q3 2025 | |
| $4.5M | 2.24% | 0.47% | New | Q3 2025 | |
| $4.49M | 2.24% | 0.02% | -33.3% | Q2 2020 | |
| $4.38M | 2.18% | 0.70% | +657.6% | Q4 2021 | |
| $4.23M | 2.11% | 0.05% | New | Q3 2025 | |
| $4.15M | 2.07% | Not reported | New | Q3 2025 | |
| $4.01M | 2.00% | Not reported | New | Q3 2025 | |
| $3.92M | 1.95% | 0.06% | -25.1% | Q1 2024 | |
| $3.81M | 1.90% | Not reported | New | Q3 2025 | |
| $3.67M | 1.83% | Not reported | New | Q3 2025 | |
| $3.37M | 1.68% | Not reported | New | Q3 2025 | |
| $3.37M | 1.68% | 0.55% | New | Q3 2025 | |
| $3.18M | 1.59% | Not reported | New | Q3 2025 | |
| $2.76M | 1.38% | 0.14% | New | Q3 2025 | |
| $2.74M | 1.36% | Not reported | Not reported | Q1 2025 | |
| $2.65M | 1.32% | Not reported | New | Q3 2025 | |
| $2.59M | 1.29% | Not reported | New | Q3 2025 | |
| $2.45M | 1.22% | 0.31% | New | Q3 2025 | |
| $2.39M | 1.19% | Not reported | New | Q3 2025 | |
| $2.33M | 1.16% | 0.06% | Not reported | Q3 2019 | |
| $2.33M | 1.16% | 0.53% | New | Q3 2025 | |
| $2.3M | 1.15% | 0.06% | New | Q3 2025 | |
| $2.22M | 1.11% | 0.16% | New | Q3 2025 | |
| ABRNAMAvidity Biosciences, Inc. | $2.18M | 1.09% | 0.03% | Not reported | Q2 2020 |
| $2.1M | 1.05% | 1.16% | New | Q3 2025 | |
| $2.08M | 1.04% | 0.03% | New | Q3 2025 | |
| CECAEPCantor Equity Partners III, Inc. | $2.06M | 1.03% | Not reported | Not reported | Q2 2025 |
| $2.06M | 1.02% | Not reported | New | Q3 2025 | |
| $1.92M | 0.96% | 0.32% | New | Q3 2025 | |
| $1.89M | 0.94% | 0.04% | New | Q3 2025 | |
| $1.44M | 0.72% | Not reported | New | Q3 2025 | |
| $1.39M | 0.69% | 0.91% | Not reported | Q1 2024 | |
| CECEPTCantor Equity Partners II, Inc. | $1.34M | 0.67% | Not reported | -14.7% | Q2 2025 |
| $1.11M | 0.55% | Not reported | Not reported | Q3 2023 | |
| $1.1M | 0.55% | 0.29% | New | Q3 2025 | |
| $1.02M | 0.51% | Not reported | New | Q3 2025 | |
| $942K | 0.47% | 0.02% | New | Q3 2025 | |
Premium opens every quarter this fund has filed